Golden State Equity Partners’s Gilead Sciences GILD Stock Holding History

Golden State Equity Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.8K	Sell	703 -68,817	-99%	-$9.07M	0.24%	60
2026 Q1	$9.69M	Buy	+69,520	New	+$9.74M	0.73%	18
2024 Q4	–	Sell	-1,034	Closed	-$86.7K	–	615
2024 Q3	$86.7K	Buy	+1,034	New	+$78.9K	0.01%	484
2023 Q4	$208K	Sell	2,564 -265	-9%	-$20.6K	0.05%	339
2023 Q3	$212K	Buy	+2,829	New	+$218K	0.06%	306
2021 Q4	–	Sell	-10,030	Closed	-$701K	–	208
2021 Q3	$701K	Sell	10,030 -4,506	-31%	-$317K	0.29%	88
2021 Q2	$1M	Sell	14,536 -2,547	-15%	-$170K	0.39%	65
2021 Q1	$1.1M	Buy	+17,083	New	+$1.1M	0.63%	44

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Golden State Equity Partners's GILD Position: Q2 2026 in Review

Golden State Equity Partners reduced its Gilead Sciences (GILD) stake by 99% in Q2 2026, selling an estimated $9.07M and leaving 703 shares worth $88.8K. The position accounts for 0.24% of the portfolio, ranked #60.

Golden State Equity Partners first reported a position in GILD in Q1 2021 and has held it in 8 quarters since. The position peaked at $9.69M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Golden State Equity Partners held 703 shares of Gilead Sciences worth $88.8K as of Q2 2026.
Golden State Equity Partners sold 68,817 Gilead Sciences shares in Q2 2026, an estimated $9.07M.
Gilead Sciences made up 0.24% of Golden State Equity Partners's portfolio in Q2 2026, its #60 holding.
Golden State Equity Partners first reported a position in Gilead Sciences in Q1 2021 and has held it in 8 quarters since.
Golden State Equity Partners's Gilead Sciences position peaked at $9.69M in Q1 2026.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.